WithdrawnNCT02952196
Cannabioids as a New Intervention for Amphetamine Dependence
Medication studyAges 18–65CanadaAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- MontrealSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: November 2016
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02952196
- Official title
Show the full official title
Cannabinoids as a New Intervention for Amphetamine Dependence: A Proof-of-concept Study
Recruitment & locations
WithdrawnMontreal
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Centre hospitalier de l'Université de Montréal (CHUM), a university.
Does this study involve medication?
Yes. The study involves medication, including drug administration.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
